Suchergebnisse - "Monchâtre-Leroy, Elodie"

PubPharm (33)

1

UTILISATION DE FAECALIBACTERIUM POUR TRAITER UNE INFECTION PAR UN VIRUS RESPIRATOIRE

enthalten in: Europäisches Patentamt | 2023

von MONCHATRE-LEROY ELODIE | BOUE FRANCK | PICARD-MEYER EVELYNE | +10

2

Investigations on SARS-CoV-2 and other coronaviruses in mink farms in France at the end of the first year of COVID-19 pandemic

enthalten in: bioRxiv.org | 2023

von Wasniewski, M. | Boué, F. | Richomme, C. | +12

3

Investigations on SARS-CoV-2 and other coronaviruses in mink farms in France at the end of the first year of COVID-19 pandemic

enthalten in: bioRxiv : the preprint server for biology | 2023

von Wasniewski, M. | Boué, F. | Richomme, C. | +12

UpdateIn: PLoS One. 2023 Aug 25;18(8):e0290444. - PMID 37624818

4

OVX033, a nucleocapsid-based vaccine candidate, provides broad-spectrum protection against SARS-CoV-2 variants in a hamster challenge model

enthalten in: Frontiers in immunology | 2023

von Primard, C. | Monchâtre-Leroy, E. | Del Campo, J. | +13

5

Investigations into SARS-CoV-2 and other coronaviruses on mink farms in France late in the first year of the COVID-19 pandemic

enthalten in: PloS one | 2023

von Wasniewski, M. | Boué, F. | Richomme, C. | +12

UpdateOf: bioRxiv. 2023 Feb 02;:. - PMID 36778275

6

Reduction in SARS-CoV-2 Virus Infectivity in Human and Hamster Feces

enthalten in: Viruses | 2022

von Wurtzer, S. | Lacote, S. | Murri, S. | +12

7

Hamster and ferret experimental infection with intranasal low dose of a single strain of SARS-CoV-2

enthalten in: bioRxiv.org | 2021

von Monchatre-Leroy, E. | Lesellier, S. | Wasniewski, M. | +11

8

Intranasal type I interferon treatment is beneficial only when administered before clinical signs onset in the SARS-CoV-2 hamster model

enthalten in: bioRxiv.org | 2021

von Bessière, P. | Wasniewski, M. | Picard-Meyer, E. | +13

9

Puumala Virus Variants Circulating in Forests of Ardennes, France : Ten Years of Genetic Evolution

enthalten in: Pathogens (Basel, Switzerland) | 2021

von Castel, G. | Monchatre-Leroy, E. | López-Roig, M. | +10

10

Intranasal type I interferon treatment is beneficial only when administered before clinical signs onset in the SARS-CoV-2 hamster model

enthalten in: PLoS pathogens | 2021

von Bessière, P. | Wasniewski, M. | Picard-Meyer, E. | +13